SMARCB1 and glioma: Even though none of our cases displayed characteristic genetic or epigenetic features of malignant glioma and none showed a component with retained SMARCB1 staining, the possibility that some ATRT–SHH expressing glial markers might rather represent unusual glial neoplasms, in which SMARCB1 deficiency may have caused epigenetic similarity with ATRT–SHH needs to be considered.